Alembic Pharmaceuticals receives USFDA tentative approval for 45 mg Binimetinib tablets

What Alembic announced

On 19 June 2026, Alembic Pharmaceuticals Limited informed the stock exchanges that it had received tentative approval from the United States Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) covering Binimetinib tablets, 45 mg. The announcement was made through a formal press release attached to a filing with both NSE and BSE. This tentative approval follows an earlier USFDA tentative nod for the 15 mg strength of the same molecule.

"Alembic Pharmaceuticals Limited receives USFDA Tentative Approval for Binimetinib Tablets, 45 mg" – press release, 19 June 2026.

The approval is a regulatory milestone that moves the product one step closer to a potential launch in the United States, subject to final FDA clearance.

Details of the USFDA tentative approval

The tentative approval pertains to Alembic’s ANDA for Binimetinib 45 mg tablets, which are therapeutically equivalent to the reference listed drug (RLD) Mektovi 15 mg tablets marketed by Array. Binimetinib is a kinase inhibitor used in combination with encorafenib for two distinct oncology indications:

• Unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.
• Metastatic non‑small cell lung cancer (NSCLC) with a BRAF V600E mutation.

Alembic is the sole first applicant to have filed an ANDA for the 45 mg strength containing a Paragraph IV certification under the Hatch‑Waxman Act. If the USFDA grants final approval, Alembic could be eligible for up to 180 days of generic marketing exclusivity in the United States, a period that can be valuable for recouping development costs and establishing market presence.

Market potential and Alembic’s USFDA track record

According to IQVIA, Binimetinib tablets have an estimated US market size of US$259 million for the twelve months ending March 2026. This figure reflects the combined demand for the melanoma and NSCLC indications in which the drug is positioned.

Alembic’s regulatory portfolio is extensive. With this tentative approval, the company now boasts a cumulative total of 242 ANDA approvals from the USFDA – 222 final approvals and 20 tentative approvals. This track record underscores Alembic’s capability to navigate the US regulatory landscape and bring generic products to market.

Key facts at a glance

Why this matters for investors

The tentative approval signals progress toward a commercial product in a high‑value oncology segment. While the approval is not final, it reduces regulatory uncertainty and positions Alembic to benefit from a sizable US market once final clearance is obtained. The Paragraph IV certification gives Alembic a unique standing as the first applicant for this strength, potentially granting it a period of market exclusivity that can improve cash‑flow prospects.

From a broader perspective, the addition of another USFDA‑approved ANDA reinforces Alembic’s diversified revenue base and its reputation as a leading generic manufacturer. Investors may view the expanding US portfolio as a hedge against domestic market volatility, though they should also note that final FDA approval and subsequent commercial launch are still pending.

Conclusion

Alembic Pharmaceuticals has secured USFDA tentative approval for its Binimetinib 45 mg tablet, adding to a robust pipeline of US generic filings. The drug targets lucrative oncology indications with an estimated US$259 million market, and the company could enjoy up to 180 days of exclusivity if final approval is granted. Final regulatory clearance remains a prerequisite for commercialisation, and investors should monitor subsequent FDA actions and any related commercial agreements.

---

FAQs

1. What is the significance of a USFDA tentative approval? Tentative approval indicates that the USFDA has found the ANDA acceptable, but the product cannot be marketed in the US until a final approval is issued, often due to pending exclusivity or patent issues.

2. When can Alembic start selling Binimetinib 45 mg tablets in the US? The company can commence sales only after receiving final USFDA approval, which may follow the tentative approval pending resolution of any exclusivity or patent matters.

3. What exclusivity benefits could Alembic obtain? If the ANDA receives final approval, Alembic may be eligible for up to 180 days of generic marketing exclusivity under the Hatch‑Waxman Act, owing to its Paragraph IV certification.

4. How large is the market for Binimetinib tablets? IQVIA estimates the US market for Binimetinib tablets at US$259 million for the twelve months ending March 2026.

5. How many USFDA ANDA approvals does Alembic have in total? Alembic has accumulated 242 ANDA approvals from the USFDA, comprising 222 final approvals and 20 tentative approvals.

6. Does the filing disclose any financial impact or revenue forecast? The press release does not provide specific revenue projections or financial impact estimates related to the Binimetinib 45 mg tablet.